Literature DB >> 20023552

Clinical and pathological characteristics of brain metastasis resected after failed radiosurgery.

Jay Jagannathan1, T David Bourne, David Schlesinger, Chun-Po Yen, Mark E Shaffrey, Edward R Laws, Jason P Sheehan.   

Abstract

OBJECTIVE: This study evaluates the tumor histopathology and clinical characteristics of patients who underwent resection of their brain metastasis after failed gamma knife radiosurgery.
METHODS: This study was a retrospective review from a prospective database. A total of 1200 brain metastases in 912 patients were treated by gamma knife radiosurgery during a 7-year period. Fifteen patients (1.6% of patients, 1.2% of all brain metastases) underwent resective surgery for either presumed tumor progression (6 patients) or worsening neurological symptoms associated with increased mass effect (9 patients). Radiographic imaging, radiosurgical and surgical treatment parameters, histopathological findings, and long-term outcomes were reviewed for all patients.
RESULTS: The mean age at the time of radiosurgery was 57 years (age range, 32-65 years). Initial pathological diagnoses included metastatic non-small cell lung carcinoma in 8 patients (53%), melanoma in 4 patients (27%), renal cell carcinoma in 2 patients (13%), and squamous cell carcinoma of the tongue in 1 patient (7%). The mean time interval between radiosurgery and surgical extirpation was 8.5 months (range, 3 weeks to 34 months). The mean treatment volume for the resected lesion at the time of radiosurgery was 4.4 cm(3) (range, 0.6-8.4 cm(3)). The mean dose to the tumor margin was 21Gy (range, 18-24 Gy). In addition to the 15 tumors that were eventually resected, a total of 32 other metastases were treated synchronously, with a 78% control rate. The mean volume immediately before surgery for the 15 resected lesions was 7.5 cm(3) (range, 3.8-10.2 cm(3)). Histological findings after radiosurgery varied from case to case and included viable tumor, necrotic tumor, vascular hyalinization, hemosiderin-laden macrophages, reactive gliosis in surrounding brain tissue, and an elevated MIB-1 proliferation index in cases with viable tumor. The mean survival for patients in whom viable tumor was identified (9.4 months) was significantly lower than that of patients in whom only necrosis was seen (15.1 months; Fisher's exact test, P < 0.05).
CONCLUSION: Radiation necrosis and tumor radioresistance are the most common causes precipitating a need for surgical resection after radiosurgery in patients with brain metastasis.

Entities:  

Mesh:

Year:  2010        PMID: 20023552     DOI: 10.1227/01.NEU.0000359318.90478.69

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  12 in total

1.  Analysis of radiation therapy in a model of triple-negative breast cancer brain metastasis.

Authors:  DeeDee Smart; Alejandra Garcia-Glaessner; Diane Palmieri; Sarah J Wong-Goodrich; Tamalee Kramp; Brunilde Gril; Sudhanshu Shukla; Tiffany Lyle; Emily Hua; Heather A Cameron; Kevin Camphausen; Patricia S Steeg
Journal:  Clin Exp Metastasis       Date:  2015-08-30       Impact factor: 5.150

2.  Pathological characteristics of spine metastases treated with high-dose single-fraction stereotactic radiosurgery.

Authors:  Evangelia Katsoulakis; Ilya Laufer; Mark Bilsky; Narasimhan P Agaram; Michael Lovelock; Yoshiya Yamada
Journal:  Neurosurg Focus       Date:  2017-01       Impact factor: 4.047

Review 3.  A comprehensive review of MR imaging changes following radiosurgery to 500 brain metastases.

Authors:  T R Patel; B J McHugh; W L Bi; F J Minja; J P S Knisely; V L Chiang
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-15       Impact factor: 3.825

4.  T2 Fluid-Attenuated Inversion Recovery Imaging of Uveal Melanomas and Other Ocular Pathology.

Authors:  Gena M Damento; Kelly K Koeller; Diva R Salomão; Jose S Pulido
Journal:  Ocul Oncol Pathol       Date:  2016-07-01

5.  Analysis of the layering pattern of the apparent diffusion coefficient (ADC) for differentiation of radiation necrosis from tumour progression.

Authors:  Jihoon Cha; Sung Tae Kim; Hyung-Jin Kim; Hye Jeong Kim; Byung-Joon Kim; Pyoung Jeon; Keon Ha Kim; Hong Sik Byun
Journal:  Eur Radiol       Date:  2012-08-19       Impact factor: 5.315

Review 6.  Imaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice.

Authors:  Jacob Ruzevick; Lawrence Kleinberg; Daniele Rigamonti
Journal:  Neurosurg Rev       Date:  2013-11-15       Impact factor: 3.042

7.  Differentiating radiation necrosis from tumor progression in brain metastases treated with stereotactic radiotherapy: utility of intravoxel incoherent motion perfusion MRI and correlation with histopathology.

Authors:  Jay S Detsky; Julia Keith; John Conklin; Sean Symons; Sten Myrehaug; Arjun Sahgal; Chinthaka C Heyn; Hany Soliman
Journal:  J Neurooncol       Date:  2017-07-03       Impact factor: 4.130

Review 8.  Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases.

Authors:  Balamurugan Vellayappan; Char Loo Tan; Clement Yong; Lih Kin Khor; Wee Yao Koh; Tseng Tsai Yeo; Jay Detsky; Simon Lo; Arjun Sahgal
Journal:  Front Oncol       Date:  2018-09-28       Impact factor: 6.244

9.  Retrospective analysis of salvage surgery for local progression of brain metastasis previously treated with stereotactic irradiation: diagnostic contribution, functional outcome, and prognostic factors.

Authors:  Koichi Mitsuya; Yoko Nakasu; Nakamasa Hayashi; Shoichi Deguchi; Takuma Oishi; Takashi Sugino; Kazuaki Yasui; Hirofumi Ogawa; Tsuyoshi Onoe; Hirofumi Asakura; Hideyuki Harada
Journal:  BMC Cancer       Date:  2020-04-17       Impact factor: 4.430

Review 10.  Radiation Necrosis from Stereotactic Radiosurgery-How Do We Mitigate?

Authors:  Balamurugan A Vellayappan; Tresa McGranahan; Jerome Graber; Lynne Taylor; Vyshak Venur; Richard Ellenbogen; Andrew E Sloan; Kristin J Redmond; Matthew Foote; Samuel T Chao; John H Suh; Eric L Chang; Arjun Sahgal; Simon S Lo
Journal:  Curr Treat Options Oncol       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.